EQRx to Participate at Upcoming Investor Conferences
EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at radically lower prices, today announced that management will participate in investor conferences in June.
EQRx Announces New Data for Lead Oncology Programs in Non-small Cell Lung Cancer and Rare Form of Non-Hodgkin Lymphoma at ASCO 2022
EQRx announced data from pivotal trials of sugemalimab, a PD-L1 inhibitor, and aumolertinib, a third-generation EGFR-tyrosine kinase inhibitor (TKI), being presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting taking place from June 3 through June 7, 2022.
EQRx Reports First Quarter 2022 Financial Results and Recent Corporate Progress
EQRx today reported financial results for the first quarter ended March 31, 2022 and provided an overview of recent corporate progress.
EQRx to Hold First Quarter 2022 Financial Results Conference Call on Friday, May 13, 2022
EQRx announced it will host a conference call and webcast on Friday, May 13, 2022 at 8:00 a.m. ET to report its first quarter 2022 financial results and provide a business update.
EQRx Announces New Data on Lead Oncology Programs to Be Presented at 2022 ASCO Annual Meeting
New data on EQRx lead oncology programs will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting taking place from June 3 through June 7, 2022.